<DOC>
	<DOCNO>NCT02258204</DOCNO>
	<brief_summary>KETA trial nonprofit , double-blind , randomize , control pilot trial aim determine co-administration ketamine recombinant tissue type plasminogen activator ( tPA ) thrombolysis acute ischemic stroke compare tPA co-administered placebo , decrease cerebral infarction growth diffusion weight imaging admission day 1 . Eligibility apply patient symptomatic ischemic stroke see within 4.5 h onset middle cerebral artery distal internal carotid artery occlusion , contraindication intravenous tPA-mediated thrombolysis eligible endovascular treatment stroke ( i.e . thrombectomy ) . The study design 80 % power detect 80 % decrease infarct volume growth tPA-ketamine group two-sided type I error rate 5 % . For purpose , least 25 patient per arm enrol .</brief_summary>
	<brief_title>Ketamine Thrombolysis Acute Ischemic Stroke</brief_title>
	<detailed_description>Rationale — Tissue-type plasminogen activator ( tPA ) double-sided molecule , beneficial effect acute ischemic stroke due intravascular fibrinolytic activity potential deleterious effect due ability potentiate neuronal N-methyl-D-aspartate ( NMDA ) receptor signal ( Nicole et al. , 2001 ) . Co-administration sub-anesthetic dose ketamine - non-competitive inhibitor NMDA receptor - show improve efficacy tPA-mediated thrombolysis follow stroke rodent ( Gakuba et al , 2011 ) . Aims — To assess efficacy safety co-administration ketamine tPA compare tPA-placebo infusion patient acute ischemic stroke . Sample size estimate —With 25 patient per group , trial 80 % probability detect 80 % decrease infarct volume growth tPA-ketamine group compare tPA-placebo group day 1 admission two-sided type I error rate 5 % . Study outcomes — The primary efficacy outcome cerebral infarction growth diffusion weight imaging admission day 1 . The primary safety measure mortality and/or symptomatic intracerebral hemorrhage rate 3 month .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Sudden focal neurological deficit attributable acute ischemic stroke . Age 18 85 . Time symptom onset less 4.5 hour . NIHSS score 7 20 . Informed consent participation . Ketamine administer within 15 minute onset tPA infusion . MRIbased AIS diagnosis . Middle cerebral ( M1 M2 segment ) and/or distal internal carotid artery occlusion . No intracranial hemorrhage MRI . Patient eligible thrombectomy . Contraindication IV tPA treatment . Contraindication ketamine . Contraindication MRI . Contraindication intravascular iodinate contrast medium . Consciousness level &gt; 1 question 1a NIHSS . Prestroke mRS ≥3 . Concomitant medical illness would interfere outcome assessment followup ( e.g . advanced cancer respiratory disease ) . Previous participation trial current participation another investigational drug trial . Infarct volume diffusion weight MRI 100 mL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Cerebral Infarct</keyword>
	<keyword>Thrombolysis</keyword>
	<keyword>Tissue-type plasminogen activator</keyword>
	<keyword>Neuroprotection</keyword>
	<keyword>Anesthetic agent</keyword>
	<keyword>Magnetic resonance imaging</keyword>
</DOC>